Loading...
Tolvaptan, hyponatremia, and heart failure
Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108793/ https://ncbi.nlm.nih.gov/pubmed/21694950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S7032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|